Varex Imaging AI Stock Analysis
Want to see VREX full AI Analyst Report?
Varex Imaging (VREX) AI Stock Analysis
Varex Imaging
(NASDAQ:VREX)
The score is led by mixed financial performance: profitability has returned, but negative free cash flow and weak cash conversion are key near-term risks. Technicals are mildly supportive with improved intermediate-term trend, while valuation is a headwind given the ~35 P/E. Corporate events add some support due to the pending all-cash acquisition, but regulatory and legal contingencies temper the benefit.
Varex Imaging (VREX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $769.86M
- Dividend Yield
- ―
- Average Volume (3M)
- 638.47K
- Price to Earnings (P/E)
- 34.6
- Beta (1Y)
- 2.20
- Revenue Growth
- 5.31%
- EPS Growth
- ―
- Country
- US
- Employees
- 2,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Varex Imaging Business Overview & Revenue Model
Company Description
Varex Imaging Corporation (VREX) specializes in the development and production of X-ray imaging components. Its operations are divided into two primary divisions: Medical and Industrial. Within the Medical segment, Varex provides a comprehensive rang...
How the Company Makes Money
Varex primarily makes money by selling imaging components and subsystems—most notably X-ray tubes and flat panel detectors—to OEM customers that build complete imaging systems for hospitals, clinics, and industrial inspection markets. Revenue is gene...
Varex Imaging Earnings Call Summary
The call highlighted solid execution on guidance, margin resilience (non‑GAAP gross margin at the high end), successful debt refinancing and clear technology and industrial pipeline momentum (CT, photon-counting, cargo systems). Offsetting these positives are modest top‑line growth (+1% YoY), a GAAP loss, margin erosion versus the prior year (down ~240 bps), elevated inventory and short‑term working capital pressures. Management provided multi-quarter visibility (annual guidance) and actions (India ramp, pricing/contract renewal levers) that could improve margins over time, but near-term growth and margin recovery remain modest.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Varex guided that second‑half fiscal 2026 revenue should be up roughly 3% year‑over‑year (guidance excludes any IEEPA tariff refund) and reiterated full‑year fiscal 2026 revenues of $860–$880 million with non‑GAAP EPS of $0.80–$1.00; Q3 guidance is $210–$225 million of revenue and non‑GAAP diluted EPS of $0.15–$0.30, based on non‑GAAP gross margin of 33–34%, non‑GAAP operating expenses of about $54 million, net interest and other expense of $6–$7 million, a Q3 tax rate of ~23% (full‑year tax expectation ~20%), and roughly 42 million diluted non‑GAAP shares outstanding, and management said it will resume providing annual guidance going forward.
Varex Imaging Financial Statement Overview
Summary
Income statement shows a recovery to profitability in TTM and relatively steady gross margins, but earnings have been volatile across recent years. Balance sheet leverage is improving and appears manageable, yet sensitivity to renewed earnings weakness remains. The biggest drag is cash flow: TTM operating cash flow is very low and free cash flow is negative, not supporting the return to net income and reducing financial flexibility.
Income Statement
64PositiveBalance Sheet
62PositiveCash Flow
45Neutral| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 865.00M | 844.60M | 811.00M | 893.40M | 859.40M | 818.10M |
| Gross Profit | 296.90M | 290.50M | 256.90M | 290.30M | 283.50M | 271.50M |
| EBITDA | 93.90M | 3.50M | 62.90M | 94.70M | 114.50M | 104.50M |
| Net Income | 22.10M | -70.30M | -47.70M | 48.20M | 30.30M | 17.40M |
Balance Sheet | ||||||
| Total Assets | 1.10B | 1.11B | 1.22B | 1.25B | 1.18B | 1.15B |
| Cash, Cash Equivalents and Short-Term Investments | 99.20M | 155.10M | 200.50M | 193.90M | 89.40M | 144.60M |
| Total Debt | 373.60M | 401.90M | 470.40M | 469.80M | 436.40M | 459.40M |
| Total Liabilities | 589.50M | 620.80M | 667.80M | 668.60M | 637.70M | 651.00M |
| Stockholders Equity | 496.60M | 472.60M | 535.10M | 567.70M | 533.40M | 483.30M |
Cash Flow | ||||||
| Free Cash Flow | -20.20M | 18.80M | 20.40M | 87.70M | -4.40M | 77.50M |
| Operating Cash Flow | 11.30M | 41.70M | 47.30M | 108.40M | 16.90M | 92.60M |
| Investing Cash Flow | -17.80M | 10.30M | -27.50M | -44.90M | -48.40M | -16.20M |
| Financing Cash Flow | -31.00M | -75.90M | -3.30M | -200.00K | -23.80M | -32.30M |
Varex Imaging Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VREX, the sentiment is Neutral. The current price of 18.10 is below the 20-day moving average (MA) of 18.39, below the 50-day MA of 18.43, and above the 200-day MA of 13.86, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 29.91 is Positive, neither overbought nor oversold. The STOCH value of 16.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VREX.
Varex Imaging Risk Analysis
Varex Imaging disclosed 36 risk factors in its most recent earnings report. Varex Imaging reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksVarex Imaging Peers Comparison
Overall Rating
GEHC79Outperform
PHG67Neutral
BRKR57Neutral
VREX57Neutral
ARAY41Neutral
NNOX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | $37.51B | 17.57 | 19.85% | 0.17% | 6.87% | -2.26% | |
| 67Neutral | $29.42B | 27.33 | 8.44% | 3.28% | ― | ― | |
| 57Neutral | $9.26B | -55.56 | -5.15% | 0.33% | 2.16% | -604.24% | |
| 57Neutral | $769.86M | 34.63 | 4.60% | ― | 5.31% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 41Neutral | $7.65M | -0.45 | -36.60% | ― | -12.50% | 5.33% | |
| 40Underperform | $25.22M | -0.19 | -94.35% | ― | 31.52% | -89.07% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VREX | Varex Imaging Corporation | 18.10 | 7.86 | 76.76% | |
| ARAY | Accuray Incorporated | 2.44 | -34.55 | -93.40% | |
| BRKR | Bruker Corporation | 61.36 | 18.15 | 42.02% | |
| PHG | Koninklijke Philips N.V. | 29.89 | 3.69 | 14.10% | |
| NNOX | Nano-X Imaging Ltd. | 0.29 | -2.74 | -90.53% | |
| GEHC | Ge Healthcare Technologies Inc. | 81.84 | 9.68 | 13.41% |
Varex Imaging Corporate Events
Varex Shareholders Approve Merger with Teledyne Technologies
PositiveOn October 28, 2026, Varex Imaging held a special meeting of stockholders to vote on proposals tied to its August 10, 2026 merger agreement with Teledyne Technologies, under which Varex would be acquired via a merger and become a wholly owned subsidi...
Varex Imaging issues supplemental disclosures amid merger lawsuits
NegativeOn August 10, 2026, Varex Imaging agreed to be acquired by Teledyne Technologies via a merger that would make Varex a wholly owned subsidiary, with shareholders to vote on the deal at a virtual special meeting scheduled for October 28, 2026. Since th...
Varex Imaging Agrees to Teledyne All-Cash Acquisition
PositiveOn August 10, 2026, Varex Imaging entered into a definitive merger agreement under which Teledyne Technologies will acquire all outstanding Varex shares for $18.90 in cash per share, valuing the deal at about $1.1 billion including equity awards and...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
